ArticleThe Journal of clinical investigation2026

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

Galina Semenova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.